Investment Plan for Europe – Successful launch of Tech Transfer Fund “KHAN-I”
Khanu Management GmbH (Khanu), a drug discovery focused fund management team, announces the successful launch of KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I), based in Dortmund, Germany.
The European Investment Fund (EIF, Luxemburg), the Austria Wirtschaftsservice GmbH (Vienna, Austria) and the Max Planck Foundation (Munich, Germany) committed in a first closing an investment of a total volume of € 60 million into KHAN-I for a period of 5 plus 2 years in early-stage drug discovery projects. The Khanu fund management team will invest a minority amount.
A PhD’s guide on how to organize a conference
Eleven Early Stage Researchers from eight different institutions including the LDC, all part of the EU DivIDE network, tell us about their experience organizing their first international conference – and what they learned on the way.
Bekämpfung resistenter Bakterien: Bundesministerium für Bildung und Forschung fördert NRW Konsortium NanoComBac mit zwei Millionen Euro
Die Lead Discovery Center GmbH (LDC) ist Teil des neuen, geförderten NRW Konsortiums NanoComBac, das sich der Entwicklung neuer antibiotischer Therapiemöglichkeiten gegen resistente Bakterien widmet.
LDC and Korean Drug Development Fund collaborate to mature innovative drug discovery projects in South Korea
Seoul, South Korea. The Lead Discovery Center (LDC) and the Korean Drug Development Fund (KDDF) have entered into an agreement to facilitate the interaction between LDC and the prospering South Korean biotech scene.
LDC Receives the City of Dortmund Business Award
The Lead Discovery Center (LDC) has won Dortmund’s Business Prize, awarded yearly by the Wirtschaftsförderung and the Sparkasse Dortmund. The distinguished jury selected the LDC for its innovative business concept and its outstanding achievements for the benefit of society. The company forms a vital link between academia and industry. In close collaboration with both partners, it helps transform great ideas into medicines that can change the lives of millions of people.
New Center of Competence for Innovative Diabetes Therapy (KomIT) is funded by NRW and EU
The Lead Discovery Center (LDC) is part of a new consortium of eight partners from industry and academia focusing on the development of new diabetes therapies.
LDC and European-Canadian Consortium Attract €1.1 Million to Develop new Therapies Against Rare Disease ATD
The Lead Discovery Center (LDC) has teamed up with McGill University in Canada, Institut National de la Santé Et de la Recherche Médicale (INSERM) in France and Semmelweis University in Hungary to discover new approaches for the treatment of alpha-1 antitrypsin deficiency (ATD), a rare genetic disorder that lead to severe lung and liver diseases. The partners receive a total of €1.1 million in funding under the transnational E-Rare-3 programme on rare diseases.
LDC and the University of Duisburg-Essen receive EUR 905,000 for the development of new therapies for age-related blindness
The Lead Discovery Center GmbH (LDC) and the University of Duisburg-Essen (UDE) have received EUR 905,000 in funding from the state of North Rhine-Westphalia as part of its lead market competition, LifeSciences.NRW. Together with the LDC’s own financial contribution, this gives the partners a total of EUR 1.3 million with which to develop new drugs for the treatment of age-related macular degeneration (AMD).
APEIRON Announces Collaboration with Lead Discovery Center GmbH
APEIRON Biologics AG, an Austrian company focused on cancer immunotherapy, today announced a collaboration agreement with the Lead Discovery Center GmbH (LDC), a translational research organization established in 2008 by Max Planck Innovation, to develop novel immune checkpoint modulators. The two companies will perform drug discovery activities to optimize and develop novel small molecules addressing immune checkpoints, important gatekeepers in cancer immunity. All molecules deriving from this collaboration are proprietary to APEIRON and will strengthen APEIRON’s development pipeline.
Grünenthal, Lead Discovery Center and Max Planck Society enter into a research collaboration on Charcot-Marie-Tooth 1A (CMT1A)
Grünenthal, Lead Discovery Center GmbH (LDC), Max-Planck Innovation and Max Planck Institute of Experimental Medicine (MPI-EM) have entered into a research collaboration to develop novel therapies for patients suffering from Charcot-Marie-Tooth 1A (CMT1A), an inherited neurological disorder.
Eleven million euros for Dortmund alliance for the development of new lead compounds
Innovative network of eight partners for North Rhine-Westphalia
Drug Discovery Hub Dortmund (DDHD) is the name of the new initiative at the Zentrum für integrierte Wirkstoffforschung (ZIW) of the TU Dortmund University (TU), which got started on 1 April 2018. Scientists from eight institutions combine their manifold expertise to develop an infrastructure for drug discovery in North Rhine-Westphalia. In addition to the TU Dortmund, the Max-Planck-Institute for Molecular Physiology (MPI), the Leibniz Research Centre for Working Environment and Human Factors (IfADo), the Leibniz-Institut für Analytische Wissenschaften - ISAS - e.V., the Taros GmbH & Co. KG, the PROvendis GmbH, the BioMedizinZentrum Dortmund (BMZ), and the Lead Discovery Center GmbH (LDC) are participating.
LDC: New branch for development of therapeutic antibodies in Munich
The Lead Discovery Center GmbH (LDC) has established a branch - LDC Biologics - in the Munich Biocluster. While the team in Dortmund focuses on chemical compounds (small molecules), in Munich the emphasis will be on the development of therapeutic antibodies.
Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Announce Cancer Research Collaboration
Daiichi Sankyo, Max Planck Innovation and LDC have signed an agreement providing Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for the treatment of cancer to be discovered and developed at LDC.
LDC and SOTIO Enter License and Collaboration Agreement for First-in-class Cancer Metabolism Program
The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH (MI) and SOTIO a.s. have signed a collaboration and license agreement providing SOTIO with exclusive rights to an oncology program addressing a novel target in tumor metabolism. It was discovered at the Max Planck Institute for Biology of Ageing and jointly advanced by the LDC and Max Planck scientists into drug discovery.
Arix Bioscience plc, LDC and University of Leeds collaborate to develop novel therapeutics for metabolic diseases
First project from LDC's agreement with Arix
Arix Bioscience plc (LSE:ARIX), a global healthcare and life science company supporting medical innovation, has signed an agreement with the Lead Discovery Center, Max Planck Innovation, and the University of Leeds to develop new therapeutics for metabolic diseases based on the discoveries from these organisations.
news & press
Response to the structural transformation of the pharma industry [German only]
Bert Klebl, Peter Nussbaumer and Matthias Stein-Gerlach; transkript | Special Issue Kapital & Börse May 2009
Polishing Medical Rough Diamonds
Text: Marcus Anhäuser
Max Planck Society Magazine Special “Innovation” / 2009
Pages 47 – 53
Joint Initiative for Research and Innovation